1. Home
  2. EPR vs MIRM Comparison

EPR vs MIRM Comparison

Compare EPR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPR
  • MIRM
  • Stock Information
  • Founded
  • EPR 1997
  • MIRM 2018
  • Country
  • EPR United States
  • MIRM United States
  • Employees
  • EPR N/A
  • MIRM N/A
  • Industry
  • EPR Real Estate Investment Trusts
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • EPR Real Estate
  • MIRM Health Care
  • Exchange
  • EPR Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • EPR 4.4B
  • MIRM 3.7B
  • IPO Year
  • EPR 1997
  • MIRM 2019
  • Fundamental
  • Price
  • EPR $51.93
  • MIRM $70.39
  • Analyst Decision
  • EPR Buy
  • MIRM Strong Buy
  • Analyst Count
  • EPR 11
  • MIRM 11
  • Target Price
  • EPR $58.06
  • MIRM $82.82
  • AVG Volume (30 Days)
  • EPR 809.5K
  • MIRM 596.2K
  • Earning Date
  • EPR 10-29-2025
  • MIRM 11-04-2025
  • Dividend Yield
  • EPR 6.91%
  • MIRM N/A
  • EPS Growth
  • EPR N/A
  • MIRM N/A
  • EPS
  • EPR 2.29
  • MIRM N/A
  • Revenue
  • EPR $707,150,000.00
  • MIRM $471,794,000.00
  • Revenue This Year
  • EPR $4.97
  • MIRM $53.14
  • Revenue Next Year
  • EPR $2.78
  • MIRM $19.83
  • P/E Ratio
  • EPR $22.43
  • MIRM N/A
  • Revenue Growth
  • EPR 3.73
  • MIRM 53.66
  • 52 Week Low
  • EPR $41.75
  • MIRM $36.88
  • 52 Week High
  • EPR $61.24
  • MIRM $78.55
  • Technical
  • Relative Strength Index (RSI)
  • EPR 50.96
  • MIRM 49.50
  • Support Level
  • EPR $50.14
  • MIRM $68.60
  • Resistance Level
  • EPR $51.66
  • MIRM $73.02
  • Average True Range (ATR)
  • EPR 0.84
  • MIRM 3.09
  • MACD
  • EPR 0.30
  • MIRM 0.07
  • Stochastic Oscillator
  • EPR 98.37
  • MIRM 51.86

About EPR EPR Properties

EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: